These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2355740)

  • 21. A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
    Bauer KS; Figg WD; Hamilton JM; Jones EC; Premkumar A; Steinberg SM; Dyer V; Linehan WM; Pluda JM; Reed E
    Clin Cancer Res; 1999 Sep; 5(9):2324-9. PubMed ID: 10499600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 23. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rhodamine 123 as a chemosensitizing agent for argon laser therapy. A new technique for treatment of superficial malignancies.
    Castro DJ; Saxton RE; Fetterman HR; Castro DJ; Ward PH
    Arch Otolaryngol Head Neck Surg; 1987 Nov; 113(11):1176-82. PubMed ID: 3663344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Argon laser phototherapy of human malignancies using rhodamine-123 as a new laser dye: the intracellular role of oxygen.
    Castro DJ; Saxton RE; Markley J; Foote CS; Fetterman HR; Castro DJ; Ward PH
    Laryngoscope; 1990 Aug; 100(8):884-91. PubMed ID: 2166193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical and biological study of androgen independent prostate cancer (AI PCa).
    Logothetis CJ; Hoosein NM; Hsieh JT
    Semin Oncol; 1994 Oct; 21(5):620-9. PubMed ID: 7524155
    [No Abstract]   [Full Text] [Related]  

  • 27. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy.
    Cox RA; Sundar S
    Br J Cancer; 2008 Jan; 98(1):238-9. PubMed ID: 18182981
    [No Abstract]   [Full Text] [Related]  

  • 28. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium.
    Long H; Crean CD; Lee WH; Cummings OW; Gabig TG
    Cancer Res; 2001 Nov; 61(21):7878-81. PubMed ID: 11691807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rhodamine 123 phototoxicity in laser-irradiated MGH-U1 human carcinoma cells studied in vitro by electron microscopy and confocal laser scanning microscopy.
    Shea CR; Sherwood ME; Flotte TJ; Chen N; Scholz M; Hasan T
    Cancer Res; 1990 Jul; 50(13):4167-72. PubMed ID: 2354461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma.
    Ip MM; Milholland RJ; Rosen F
    Cancer Res; 1980 Jul; 40(7):2188-93. PubMed ID: 7388787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion.
    Ip MM; Sylvester PW; Schenkel L
    Cancer Res; 1986 Apr; 46(4 Pt 1):1735-40. PubMed ID: 3948162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Animal models and treatment of prostate cancer.
    Pollard M; Luckert PH
    Prostate; 1984; 5(6):661-8. PubMed ID: 6494061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of nonhormonal cytotoxic chemotherapy in the Nb rat prostate adenocarcinoma: autonomous tumor (18-Pr and 13-Pr).
    Drago JR; Goldman LB; Gershwin ME
    Cancer; 1980 Jul; 46(2):273-8. PubMed ID: 7388771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estradiol decreases retention of rhodamine 123 fluorescence in GH4C1 pituitary tumor cells.
    Van Itallie CM; Kieffer LJ; Carbone R; Dannies PS
    Mol Endocrinol; 1990 Jan; 4(1):140-5. PubMed ID: 2325664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
    Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
    Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
    Walsh PC
    J Urol; 2005 Jun; 173(6):1966. PubMed ID: 15879792
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterization of apoptosis in prostatic androgen-independent cell lines.
    Salido M; López A; Aparicio J; Larran J; Vilches J
    Int J Dev Biol; 1996; Suppl 1():191S-192S. PubMed ID: 9087756
    [No Abstract]   [Full Text] [Related]  

  • 38. Absence of preferential uptake of [125I]iododihydrorhodamine 123 by four human tumor xenografts.
    Kinsey BM; Van den Abbeele AD; Adelstein SJ; Kassis AI
    Cancer Res; 1989 Nov; 49(21):5986-8. PubMed ID: 2676153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental treatment of prostatic cancer by intermittent hormonal therapy.
    Trachtenberg J
    J Urol; 1987 Apr; 137(4):785-8. PubMed ID: 3560348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
    Oh WK; Manola J; Bittmann L; Brufsky A; Kaplan ID; Smith MR; Kaufman DS; Kantoff PW
    Urology; 2003 Jul; 62(1):99-104. PubMed ID: 12837431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.